Invenra and Orion Corporation, a globally operating pharmaceutical company, announced recently that they have entered into a research collaboration to discover bispecific antibodies using Invenra’s B-Body platform.
“This collaboration highlights the strength and versatility of our B-Body platform in addressing complex biological challenges,” Invera CEO Roland Green said in a statement. “We are thrilled to work with Orion, a company that shares our commitment to delivering innovative therapies that address critical unmet medical needs.”
According to a release, Invenra will leverage its B-Body bispecific antibody platform from monoclonal antibody discovery to optimized panels of bispecific leads.
The collaboration will combine Invenra’s advanced engineering expertise in bispecific antibody discovery with Orion’s established track record in pharmaceutical innovation.
Financial details of the collaboration were not disclosed.